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A B S T R A C T
Varicella zoster virus (VZV) pneumonia is associated with signiﬁcant mortality, especially in the
immunocompromised host. VZV-speciﬁc immunoglobulins (VZIG) are currently used as post-exposure
prophylaxis for at-risk patients, but not as adjunctive therapy. A novel case of VZV pneumonia in an
immunocompromised patient, treated successfully with intravenous VZIG in combination with acyclovir,
is reported here.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pneumonia is a major complication of varicella zoster virus
(VZV) infection in adults (Gershon and Gershon, 2013). Suscepti-
bility is 25-fold greater in adults than in children, and risk factors
such as chronic lung disease and immunosuppression have been
associated with higher frequency and mortality rates (Puch-
hammer-stöckl and Aberle, 2015). The main treatment of severe
VZV infection consists of high-dose intravenous acyclovir together
with supportive intensive care (Gershon et al., 2015; Mirouse et al.,
2017). Despite a small number of case reports indicating positive
outcomes with the use of standard intravenous immunoglobulins
(IVIG) for disseminated varicella in pediatric patients (Prader et al.,
2018; Yamada et al., 2015), no data are available on the use of
intravenous VZV-speciﬁc IgG (VZIG) in the treatment of severe VZV
infections.* Corresponding author at: Infectious Diseases Unit, Department of Internal
Medicine, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Via
Francesco Sforza 35, 20122, Milan, Italy.
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https://doi.org/10.1016/j.ijid.2019.05.022
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Case report
We report on a 39-year-old man from Sri Lanka. His past medical
history was unremarkable until December 2017, when he suffered
from acute myocardial infarction complicated by cariogenic shock
and ventricular tachycardia, treated with amiodarone and the
implantation of a cardioverter deﬁbrillator. In August 2018, the
patient suffered from a new episode of cardiogenic shock and
respiratory distress triggered by pneumonia. Cardiac function was
severely compromised, with evidence of dilated cardiomyopathy
(ejection fraction (EF) of 25%). As respiratory impairment continued
despite several courses of antibiotics, amiodarone pulmonary
toxicity was diagnosed and the patient was discharged home on
steroids (prednisone 25 mg every 24 h).
Two months later, after a transient exposure to a child with
chickenpox, he presented to the emergency department for
hyperpyrexia, severe dyspnea, and an itchy generalized maculo-
papular to vesicular rash. Blood tests revealed hypoxemia,
respiratory acidosis, elevated liver enzymes, and acute renal
failure (Figure 1). Chest radiography showed bilateral lung
opacities. The patient was placed on non-invasive ventilation
and transferred to the intensive care unit (ICU), where empirical
antibiotic and antiviral therapy with piperacillin–tazobactam 4.5 g
every 6 h, azithromycin 500 mg every 24 h, oseltamivir 75 mg every
12 h, and acyclovir 10 mg/kg every 8 h was started. Microbiological
investigations conﬁrmed the clinical suspicion of varicellaciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Treatment regimens and clinical and laboratory data from intensive care unit admission to antibiotic and antiviral discontinuation. Improvements in both clinical
and biochemical parameters can be noted after intravenous administration of varicella zoster virus-speciﬁc immunoglobulins (VZIG).
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860 genome equivalents/ml (real-time PCR, normal value <250
genome equivalents/ml)), while cultures of blood and bronchial
aspirate, urinary antigens for Streptococcus pneumoniae and
Legionella pneumophila, and multiplex PCR for respiratory viruses
from a nasopharyngeal swab were all negative.As cardiac function and renal function were severely compro-
mised with an EF of 10–15% and oliguria, dobutamine and
continuous infusion of loop diuretics were necessary. Due to the
unstable cardiac and respiratory conditions, a bronchoalveolar
lavage could not be performed, but chest computed tomography
showed bilateral ground glass opacities, hilar lymphadenopathy,
Figure 2. Lung computed tomography scan showing bilateral patchy ground glass
opacities, peribronchial thickening, hilar lymphadenopathy, and well-deﬁned
subcentimeter nodules. These ﬁndings are typical of varicella pneumonia, as
discussed by Koo et al. (2018).
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pneumonia (Koo et al., 2018) (Figure 2). Intravenous VZIG 30 IU/kg
(2000 IU) in a single dose was therefore added. The patient’s
hemodynamic, renal, and respiratory functions gradually im-
proved, enabling the weaning of vasoactive and ventilatory
support, as well as the de-escalation of antibiotic therapy (Figure
1). Eight days after ICU admission, the patient was transferred to
the cardiology department, where respiratory function progres-
sively recovered and cardiac function slowly returned to pre-event
values. His fever and alteration of systemic inﬂammatory markers
resolved, leading to the complete discontinuation of antimicrobial
therapy. The patient was then transferred to the cardiac rehabili-
tation center in a stable clinical condition.
Discussion
This article reports a case of severe VZV pneumonia in an
immunocompromised patient, treated successfully with intrave-
nous VZIG in conjunction with high-dose acyclovir.
VZV pneumonia is one of the most frequent complications of
varicella in healthy adults. The presence of an underlying immune
deﬁciency is associated with higher rates of ICU admission,
mechanical ventilation, and mortality (Gershon et al., 2015).
Recently, Mirouse et al. reviewed 102 cases of community-acquired
VZV pneumonia in adults admitted to 29 ICUs in France. Patients
were young (median age of 39 years) and approximately half of
them were immunocompromised. Overall hospital mortality was
24%. Interestingly, one patient did receive VZIG in addition to
acyclovir, although the doses and timing were not reported
(Mirouse et al., 2017).
Passive immunotherapy is currently recommended in several
bacterial and viral infections for the protection of seronegative
hosts, either as prophylaxis or treatment (Bozzo and Jorquera,
2017). Timing is crucial: immunoglobulins are highly effective in
the early post-exposure period and their efﬁcacy then generally
decreases with disease progression (Slifka and Amanna, 2018). Yet,
when initiated shortly after symptom onset, passive immunother-
apy can be highly successful for severe or even life-threatening
infections such as hemorrhagic fever, tetanus, and botulism (Bozzo
and Jorquera, 2017). Depending on the type of infectious disease,
standard (non-speciﬁc) or hyperimmune (high-titer IgG-speciﬁc)
immunoglobulins can be administered. The latter have severaladvantages over standard immunoglobulins, such as a highly
speciﬁc activity, a standardized potency, and a more rapid viral
clearance (Slifka and Amanna, 2018). In VZV infection, hyperim-
mune VZIG are preferred, although standard IVIG may be
considered if VZIG are not available (Bozzo and Jorquera, 2017).
VZIG are currently recommended as post-exposure prophylaxis
in at-risk patients with the aim of reducing the severity of varicella.
The US Centers for Disease Control and Prevention (CDC) deﬁnition
of high-risk groups for VZV infection includes the immunocom-
promised host (patients treated with steroids, cytostatic agents,
radiotherapy, recent stem cell transplantation, or with an
immunodeﬁciency disorder not receiving replacement therapy
with immunoglobulins), pregnant women, neonates born to a
seronegative mother or whose mother develops varicella shortly
before or after delivery, and extremely premature infants
irrespective of maternal immunity status (CDC, 2013). Recently,
however, a more restricted use of VZIG prophylaxis has been
suggested in immunocompromised hosts exposed to VZV, due to
its high cost and limited availability (Harrington and Haque, 2018).
The US Food and Drug Administration (FDA)-approved VZIG –
VariZIG (Cangene Corporation, Canada) – is administered via
intramuscular route at a weight-based dosage within no more than
10 days (ideally within 96 h) after the exposure (FDA (online),
accessed 2019). Varitect CP (Biotest Pharma, Germany) is the
intravenous formulation of VZIG available in several European
countries, although not yet approved by the FDA (Pinot de Moira
and Nardone, 2005). Its therapeutic indications for post-exposure
prophylaxis are the same as those for VariZIG, but it is also licensed
as adjuvant therapy for severe VZV infections in immunocompro-
mised patients or newborns at risk of dissemination. Varitect CP is
administered intravenously at 25 IU/kg (1 ml/kg) for prophylaxis
and 25–50 IU/ml (1–2 ml/kg) for treatment. As post-exposure
prophylaxis it should be administered no later than 96 h after
exposure, while as adjunctive therapy, additional administrations
can be performed depending on the course of clinical manifes-
tations (Biotest Pharma (online), accessed 2019). Unfortunately,
this product is not available in all countries and shortages
frequently occur.
Adverse events (AEs) have been reported after standard and
varicella-speciﬁc IVIG administration, the majority being transient
and mild, such as ﬂushing, headache, and ﬂu-like symptoms. Rare
serious AEs can occur, mainly related to the infusion rate
(hypersensitivity reactions) or in patients with pre-existing risk
factors (renal impairment or thromboembolic events) (Biotest
Pharma (online), accessed 2019; Guo et al., 2018). In the case
described above, no drug-related AEs occurred after a single
infusion of high-dose intravenous VZIG (30 IU/kg, 2000 IU).
Over recent years, a few case reports have shown positive
results associated with the use of standard IVIG as adjunctive
treatment for disseminated varicella infections, mainly in immu-
nocompromised pediatric patients or solid organ transplant
recipients. Dosages have varied from 125 mg/kg/day to 1 g/kg/
day with different treatment durations (Carby et al., 2007; Kim
et al., 2014; Lu et al., 2011; Prader et al., 2018; Sulliger et al., 1984;
Tokat et al., 2001; Vales-Albertos et al., 2006; Yamada et al., 2015).
No studies are available on the efﬁcacy of intravenous VZIG in the
treatment of severe varicella infections in at-risk patients. To the
best of our knowledge it appears that the case reported here is
novel in describing a positive outcome associated with the use of
intravenous VZIG in addition to acyclovir in an adult patient with
severe VZV pneumonia. Further studies, ideally randomized trials
comparing acyclovir alone to VZIG plus acyclovir, are warranted to
support the effectiveness of VZIG in the treatment of severe
varicella infections in immunocompromised patients. Until then,
we deem that infectious diseases specialists and intensive care
physicians should consider adjunctive therapy with intravenous
D. Mangioni et al. / International Journal of Infectious Diseases 85 (2019) 70–73 73VZIG in immunocompromised critically ill patients during the
early stage of the disease. Since the number of immunocompro-
mised individuals at high risk of VZV infection is on the rise,
hospitals and national health agencies should increase their efforts




There are no ﬁnancial conﬂicts of interest to disclose.
Ethical approval
Not applicable. A copy of the written consent form signed by the




Biotest Pharma. Varitect1 CP - summary of product characteristics. http://www.
choroby-zakazne.pl/uploads/Varitect%20CP%20ang.pdf. [Accessed 2 April
2019].
Bozzo J, Jorquera JI.Useof human immunoglobulinsas ananti-infective treatment: the
experience so far and their possible re-emerging role. Expert Rev Anti Infect Ther
2017;15(6):585–604, doi:http://dx.doi.org/10.1080/14787210.2017.1328278.
Carby M, Jones A, Burke M, Hall A, Banner N. Varicella infection after heart and lung
transplantation: a single-center experience. J Heart Lung Transplant 2007;26
(4):399–402, doi:http://dx.doi.org/10.1016/j.healun.2007.01.007.
Gershon AA, Gershon MD. Pathogenesis and current approaches to control of
varicella-zoster virus infections. Clin Microbiol Rev 2013;26(4):728–43, doi:
http://dx.doi.org/10.1128/CMR.00052-13.
Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster
virus infection. Nat Rev Dis Primers 2015;15016, doi:http://dx.doi.org/10.1038/
nrdp.2015.16.
Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front
Immunol 2018;9:, doi:http://dx.doi.org/10.3389/ﬁmmu.2018.01299.Harrington D, Haque T. varicella zoster immunoglobulin G (VZIG)—do current
guidelines advocate overuse?. J Clin Virol 2018;103:25–6, doi:http://dx.doi.org/
10.1016/j.jcv.2018.03.007.
Kim J, Kwon D, Bae E, Han S, Lee J, Chung N, et al. Use of intravenous
immunoglobulin in a disseminated varicella infection in an immunocompro-
mised child. Korean J Pediatr 2014;57(8):370–3, doi:http://dx.doi.org/10.3345/
kjp.2014.57.8.370.
Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CT features of viral
pneumonia. RadioGraphics 2018;38(3):719–39, doi:http://dx.doi.org/10.1148/
rg.2018170048.
Lu Y, Fan HC, Wang CC, Cheng SN. Concomitant use of acyclovir and intravenous
immunoglobulin rescues an immunocompromised child with disseminated
varicella caused multiple organ failure. J Pediatr Hematol Oncol 2011;33(8):
e350–1, doi:http://dx.doi.org/10.1097/mph.0b013e3181ec0efb.
Mirouse A, Vignon P, Piron P, Robert R, Papazian L, Géri G, et al. Severe varicella-
zoster virus pneumonia: a multicenter cohort study. Crit Care 2017;21(1), doi:
http://dx.doi.org/10.1186/s13054-017-1731-0.
Pinot de Moira A, Nardone A. Varicella zoster virus vaccination policies and
surveillance strategies in Europe. Euro Surveill 2005;10(1):43–5.
Prader S, Felber M, Volkmer B, Trück J, Schwieger-Briel A, Theiler M, et al. Life-
threatening primary varicella zoster virus infection with hemophagocytic
lymphohistiocytosis-like disease in GATA2 haploinsufﬁciency accompanied by
expansion of double negative T-lymphocytes. Front Immunol 2018;9:, doi:
http://dx.doi.org/10.3389/ﬁmmu.2018.02766.
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